logo/base Created with Sketch.

An innovative company dedicated to liver health

wave

Our vision & our mission

We are shaping the future of liver health.

 

We are empowering medical professionals to manage liver health for simpler, faster and better patient care.  

wave

More about echosens

317

employees over eight subsidiaries

82

distributors over the world

125

international patents granted

12%

of annual sales invested in product development

Discover Echosens and our commitment for liver health in video

play
quote

It’s about passionate and humble people that make us see simplicity out of complexity.
Before becoming a company, echosens was an idea. This idea has been growing from its root in Paris, within Prof. Fink’s lab. Initially, my PhD thesis paved the way for the development of transient elastography (TE), which we patented in 1999.

> 20 years of liver health – Continue the story

Laurent Sandrin | Founder and Chief Technology Officer at Echosens

In immersion at Echosens

play

Based on our values, Echosens is committed to achieving the Sustainable Development Goals

The overall EcoVadis score obtained reflects the quality of the company’s ESG program.

Echosens has been awarded the silver medal and its score puts it among the top 25% of companies in its business sector.

c Courage
h Humility
o Openness
i Innovation
c Commitment
e Environment
s Simplicity

Inception in Paris

After Laurent Sandrin’s PhD thesis on transient elastography (TE), this technology found its application to quantify liver stiffness (LSM by VCTE) allowing a better patient care in hepatology…

First accomplishment: FibroScan® is born

The very first FibroScan® launched on the market is the FibroScan® 502. It was released during the EASL Congress in Geneva.

CAP™ parameter

In addition to VCTE, Echosens introduced a new, unique and patented technology calledCAP™ (Controlled Attenuation Parameter) for liver steatosis assessment, a true benefit to measure patient’s liver fat.

FibroScan® mobile generation

With FibroScan® Mini+ 430 and FibroScan® Compact 530, the FibroScan® family evolves to better fit physicians daily practice with mobility, user-friendliness and connectivity, ideal for multi-site configuration.

FibroScan®-based Score:
Fast™

Fast is the optimal point-of-care comprehensive test for the identification of at risk NASH patients.

FibroScan® Expert 630

The complete non-invasive solution for advanced liver disease management, with the new Spleen Stiffness Measurement (SSM by VCTE™).

FibroScan®-based Score:
Agile 3+ and Agile 4

Agile 3+ for identification of advanced fibrosis in NAFLD patients.
Agile 4 for identification of cirrhosis in NAFLD patients.

FibroScan® GO

Leadership team

Dominique Legros
Group Chief Executive Officer
Jon Gingrich
Chief Executive Officer North America
Lijuan Deng
Chief Executive Officer China
Laurent Sandrin
Founder and Chief Technology Officer